Indivior won a temporary restraining order against Dr. Reddy’s to prevent the company from rolling out its generic version of the opioid addiction treatment Suboxone (buprenorphine and naloxone) following the FDA’s approval of the generic last week.
On Friday, the U.S. District Court for the District of New Jersey granted Indivior a temporary restraining order under which Dr. Reddy’s must immediately halt the launch of the generic. The order will remain in place until a hearing scheduled for June 28.
Indivior filed a patent infringement lawsuit against Dr. Reddy’s in February but the company chose to launch its generic while the case plays out. If Dr. Reddy’s prevails in the lawsuit, Indivior will have to pay $18 million to compensate for losses incurred while the restraining order was in effect, according to the generic drugmaker.
Indivior CEO Shaun Thaxter said the company “will continue to pursue all legal avenues” against Dr. Reddy’s to protect its Suboxone film patents.